{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:12:40Z","timestamp":1790683960138,"version":"4.1.0"},"reference-count":9,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["IJU Case Reports"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Gastroenterocolitis is one of the adverse events related to immune checkpoint inhibitors. However, inflammation of the intestinal lesion used for urinary diversion is not well known as an adverse event related to their use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A patient with metastatic bladder cancer was administered pembrolizumab as second\u2010line treatment. After 12\u2009days of administration, he felt abdominal distention. Computed tomography demonstrated thickening of the ileal conduit wall and bilateral hydronephrosis. Biopsy of the ileal conduit revealed inflammatory granulation tissue. Biopsy of the sigmoid colon also revealed colitis. Therefore, we diagnosed enterocolitis including the ileal conduit related to pembrolizumab. We then started to administer 30\u2009mg prednisolone. After this treatment, we confirmed improvement of the clinical symptoms and healing of the ileal conduit mucosa.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Inflammation of an ileal conduit can occur as an immune\u2010related adverse event caused by metastatic urothelial carcinoma treatment with pembrolizumab.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iju5.12797","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:38:08Z","timestamp":1728923888000},"page":"24-27","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enteritis of the ileal conduit as an adverse event related to immune checkpoint inhibitor use"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6995-6930","authenticated-orcid":false,"given":"Ko","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Masumori","sequence":"additional","affiliation":[{"name":"Department of Urology Sapporo Medical University School of Medicine  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","article-title":"Immune checkpoint inhibitors for urothelial carcinoma","volume":"59","author":"Kim HS","year":"2018","journal-title":"Investig. Clin. Urol."},{"key":"e_1_2_12_3_1","unstructured":"FlaigTW SpiessPE AbernMet\u00a0al.NCCN Clinical Practice Guidelines in Oncology Bladder Cancer Version 4.2024https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle\u2010invasive urothelial carcinoma","volume":"384","author":"Bajorin DF","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","article-title":"Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta\u2010analysis","volume":"81","author":"Wu Z","year":"2022","journal-title":"Eur. Urol."},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD\u20101 inhibitor gastroenterocolitis: case series and appraisal of \u2018immunomadulatory gastroenterocolitis\u2019","volume":"70","author":"Gonzalez RS","year":"2017","journal-title":"Histopathology"},{"key":"e_1_2_12_7_1","unstructured":"ThompsonJA SchneiderBJ BrahmerJet\u00a0al.NCCN Clinical Practice Guidelines in Oncology Management of Immunotherapy\u2010Related Toxicities Version 1.2024."},{"key":"e_1_2_12_8_1","volume-title":"JSMO Cancer Immunotherapy Guidelines","year":"2023"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/iju.14210","article-title":"Clinical practice guidelines for bladder cancer 2019 edition by the Japanese Urological Association: revision working position paper","volume":"27","author":"Matsumoto H","year":"2020","journal-title":"Int. J. Urol."},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/ibd\/izad229","article-title":"Focus on immune checkpoint inhibitors\u2010related intestinal inflammation: from pathogenesis to therapeutical approach","volume":"30","author":"Del Gaudio A","year":"2024","journal-title":"Inflamm. Bowel Dis."}],"container-title":["IJU Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.12797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T23:35:44Z","timestamp":1735774544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iju5.12797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/iju5.12797"],"URL":"https:\/\/doi.org\/10.1002\/iju5.12797","archive":["Portico"],"relation":{},"ISSN":["2577-171X","2577-171X"],"issn-type":[{"value":"2577-171X","type":"print"},{"value":"2577-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"2024-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}